|
|
|
Volumn 2009, Issue , 2009, Pages 168-172
|
|
Clinician adoption of genetic testing for drug metabolizing enzymes: is patient safety the low-hanging fruit of personalized medicine?
a
a
Toronto Canada
(Israel)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYP2C9 PROTEIN, HUMAN;
UNSPECIFIC MONOOXYGENASE;
ARTICLE;
GENETICS;
HUMAN;
MASS COMMUNICATION;
PERSONALIZED MEDICINE;
PHARMACOGENETICS;
UTILIZATION REVIEW;
ARYL HYDROCARBON HYDROXYLASES;
DIFFUSION OF INNOVATION;
HUMANS;
INDIVIDUALIZED MEDICINE;
PHARMACOGENETICS;
|
|
EID: 79953769192
PISSN: None
EISSN: 1942597X
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
